VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2022 | Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, provides an overview of the gastrointestinal, liver, effusion, and renal safety characterization with the use of bosutinib in patients enrolled in the BFORE trial (NCT02130557). BFORE is a Phase III study evaluating the efficacy and safety of bosutinib versus imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). The safety profiles of bosutinib and imatinib in BFORE were distinct, with no new safety signals identified after 5 years of follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter